EGFR and neoplasm: The presence of common EGFR mutations (i.e., exon19 deletions, exon21 L858R) are highly predictive for response to TKI therapy; however, in case of uncommon mutations, less is known regarding their clinical relevance and tumor TKI responses may vary greatly between different uncommon mutations.